Regeneron Pharmaceuticals said the company will vigorously defend federal charges of being involved in a kickback scheme to bolster sales of the blockbuster macular degeneration drug Eylea.

Stealth BioTherapeutics Corp.’s shares crashed after the company’s lead neuromuscular disorder product candidate failed to help patients walk better and reduce fatigue.